<DOC>
	<DOCNO>NCT00877006</DOCNO>
	<brief_summary>The primary objective study compare complete response ( CR ) rate bendamustine rituximab ( BR ) standard treatment regimens either rituximab , cyclophosphamide , vincristine , prednisone ( R-CVP ) rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ( R-CHOP ) patient advance , indolent non-Hodgkin 's lymphoma ( NHL ) mantle cell lymphoma ( MCL ) .</brief_summary>
	<brief_title>Study Bendamustine Hydrochloride Rituximab ( BR ) Compared With R-CVP R-CHOP First-Line Treatment Patients With Advanced Indolent Non-Hodgkin 's Lymphoma ( NHL ) Mantle Cell Lymphoma ( MCL ) - Referred BRIGHT Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Key Histopathologic confirmation one follow cluster differentiation antigen 20 positive ( CD20+ ) Bcell nonHodgkin 's lymphoma ( tissue diagnostic procedure must perform within 6 month study entry biopsy material available review ) : follicular lymphoma ( NCI CTCAE grade 1 2 ) immunoplasmacytoma/immunocytoma ( Waldenstrom 's macroglobulinemia ) splenic marginal zone Bcell lymphoma extranodal marginal zone lymphoma mucosaassociated lymphoid tumor ( MALT ) type nodal marginal zone Bcell lymphoma mantle cell lymphoma Meets one follow needfortreatment criterion ( exception mantle cell lymphoma treatment indicate ) : presence least one follow Bsymptoms : 1. fever ( &gt; 38ºC ) unclear etiology 2. night sweat 3. weight loss great 10 % within prior 6 month large tumor mass ( bulky disease ) presence lymphomarelated complication , include narrow ureter bile duct , tumorrelated compression vital organ , lymphomainduced pain , cytopenia related lymphoma/leukemia , splenomegaly , pleural effusion , ascites hyperviscosity syndrome due monoclonal gammopathy CD20+ B cell lymph node biopsy lymphoma pathology specimen . No prior treatment ( patient `` watch wait '' may enter study recent biopsy [ obtain within last 6 month ] available ) Adequate hematologic function ( unless abnormality relate lymphoma infiltration bone marrow hypersplenism due lymphoma ) follow : hemoglobin &gt; = 10.0 g/dL absolute neutrophil count ( ANC ) &gt; =1.5*10^9/L platelet count &gt; =100*10^9/L Bidimensionally measurable disease ( field previously radiate ) Able provide write informed consent Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; =2 Estimated life expectancy &gt; =6 month Serum creatinine &lt; =2.0 mg/dL creatinine clearance &gt; =50 mL/min Alanine aminotransferase ( ALT ) aspartate transaminase ( AST ) ≤2.5*upper limit normal ( ULN ) , alkaline phosphatase total bilirubin within normal limit Left ventricular ejection fraction ( LVEF ) &gt; = 50 % multiple gated acquisition scan ( MUGA ) cardiac echocardiogram ( ECHO ) , prior patient treat RCHOP A medically accept method contraception use woman childbearing potential ( surgically sterile least 12 month naturally postmenopausal ) Men capable produce offspring surgically sterile must practice abstinence use barrier method birth control . Key Chronic lymphocytic leukemia , small lymphocytic lymphoma ( SLL ) , grade 3 follicular lymphoma Transformed disease ( bone marrow blast permit ; however , transform disease indicate leukemic involvement permit ) Central nervous system ( CNS ) lymphomatous involvement leptomeningeal lymphoma Prior radiation NHL , except single course locally delimit radiation therapy radiation field exceed 2 adjacent lymph node region Active malignancy , NHL , within past 3 year except localized prostate cancer treat hormone therapy , cervical carcinoma situ , breast cancer situ , nonmelanoma skin cancer follow definitive treatment New York Heart Association ( NYHA ) Class III IV heart failure , arrhythmia unstable angina , electrocardiograph ( ECG ) evidence active ischemia active conduction system abnormality , myocardial infarction within last 6 month ( prior study entry , ECG abnormalities screen must document investigator medically relevant ) Known human immunodeficiency virus ( HIV ) positivity Active hepatitis B hepatitis C infection ( hepatitis B surface antigen test require ) Women pregnant lactating Corticosteroids treatment lymphoma within 28 day study entry Chronically administer lowdose corticosteroid ( e.g. , prednisone ≤20 mg/day ) indication lymphoma lymphomarelated complication permit Any serious uncontrolled , medical psychological disorder would impair ability patient receive therapy Any condition place patient unacceptable risk confounds ability investigator interpret study data Any investigational agent within 28 day study entry Known hypersensitivity bendamustine , mannitol , studyrelated drug Ann Arbor stage I disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>